A novel missense mutation in F9 gene causes hemophilia B in a family with clinical variability.
暂无分享,去创建一个
Meng Li | Z. Qin | Qinle Zhang | Mengting Li | Qi Yang | Sheng Yi | Limei Huang | Jingsi Luo | Y. Zuo | X. Fan | Yingchi Lu | Shihan Feng
[1] X. Qin,et al. Comprehensive analysis of phenotypes and genetics in 21 Chinese families with haemophilia B: characterization of five novel mutations , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[2] S. Perkins,et al. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B , 2013, Journal of thrombosis and haemostasis : JTH.
[3] A. Goodeve,et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B , 2012, Thrombosis and Haemostasis.
[4] A. Bitonti,et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. , 2012, Blood.
[5] L. Aledort. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] S. Chavali,et al. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. , 2009, Genomics.
[7] Amitabh Sharma,et al. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX , 2008, Proteins.
[8] A. Srivastava,et al. The phenotypic heterogeneity of severe hemophilia. , 2008, Seminars in thrombosis and hemostasis.
[9] Alan R. Cohen,et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.
[10] K. Fischer,et al. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.
[11] D. Stafford. The vitamin K cycle , 2005, Journal of thrombosis and haemostasis : JTH.
[12] V. Blanchette,et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. , 2005, Blood.
[13] B. Furie,et al. Crystal Structure of the Calcium-stabilized Human Factor IX Gla Domain Bound to a Conformation-specific Anti-factor IX Antibody* , 2004, Journal of Biological Chemistry.
[14] K. Pasi,et al. Haemophilias A and B , 2003, The Lancet.
[15] M. Griesshammer,et al. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[16] C. Kessler,et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2001, Blood.
[17] E. Beutler,et al. Perspectives (145 articles) , 2013 .
[18] M. Goossens,et al. Haemophilia B (sixth edition): a database of point mutations and short additions and deletions , 1996, Nucleic Acids Res..
[19] K. Kurachi,et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). , 1985, Biochemistry.